D-0340-2022 Class II Terminated

Recalled by Perrigo Company PLC — Allegan, MI

FDA drug recall D-0340-2022 was initiated by Perrigo Company PLC on Jul 27, 2021 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing. The recall status is terminated (terminated Nov 8, 2022). Affected quantity: 13,920 containers.

Recall details

Product Type
Drugs
Report Date
Jan 12, 2022
Initiation Date
Jul 27, 2021
Termination Date
Nov 8, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
13,920 containers

Product description

H.E.B Allergy Relief, Fexofenadine Hydrochloride tablets, 24HR, 180mg/Antihistamine packaged as a) 15 count bottle, NDC 37808-571-22, UPC 0 41220 53081 6; b) 30 count bottle, NDC 37808-571-39, UPC 0 41220 53082 3; c) 45 count bottle, NDC 37808-571-95, UPC 0 41220 53083 0; Made with Pride & Care for H.E.B. San Antonio TX 78204, Product of Czech Republic,

Reason for recall

Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.

Distribution pattern

Nationwide in the USA

Code information

Lot a) 0HE2530, Exp 12/31/2021; 0JE2407, Exp 2/28/2022: b) 1BR0462, Exp 10/31/2022 c) 0FR0460, Exp 2/28/2022: 0LR0363, Exp 6/30/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0340-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0340-2022. Report a data issue: hello@regdatalab.com.